GlassScriptPhysician profile
Jarrod Griffis
NPI 1720516784
$4,077.12
in general payments reported to CMS, 2019-2025
21 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $59.13 · 2021: $167 · 2022: $201 · 2023: $732 · 2024: $1,066 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,035 · Travel and Lodging: $199 · Consulting Fee: $191 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.97 |
| Travel and Lodging | $199.00 |
| Consulting Fee | $191.00 |
| Entertainment | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $918.09 | 2021-2025 | Precision7, Total30, Hydrus Microstent |
| Coopervision INC. | $879.54 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Oyster Point Pharma, INC. | $299.49 | 2023-2024 | Tyrvaya |
| Lkc Technologies, INC. | $240.31 | 2024-2025 | |
| Allergan, INC. | $158.89 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.23 | 2019-2021 | |
| Biotissue Holdings INC. | $144.09 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Apellis Pharmaceuticals, INC. | $121.84 | 2024 | Syfovre |
| Dompe US, INC. | $121.60 | 2024 | Oxervate |
| Amgen INC. | $118.52 | 2025 | Tepezza |
| Optos, INC. | $113.97 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $111.79 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $108.37 | 2024 | |
| Lombart Brothers, INC. | $100.58 | 2025 | Opd-III |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $91.39 | 2025 | Tearcare System |
| Bausch & Lomb Americas INC. | $86.14 | 2022-2024 | Infuse |
| Abbvie INC. | $65.76 | 2022-2023 | |
| Topcon Healthcare, INC. | $64.04 | 2024 | |
| Carl Zeiss Meditec, INC. | $36.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarrod Griffis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.